<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Glycemic control in critically ill adult and pediatric patients
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Glycemic control in critically ill adult and pediatric patients
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Glycemic control in critically ill adult and pediatric patients
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Renee D Stapleton, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daren K Heyland, MD, FRCPC, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Polly E Parsons, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Adrienne G Randolph, MD, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uncontrolled hyperglycemia is common in critically ill patients (also called stress hyperglycemia or critical illness hyperglycemia). In this population, both hyperglycemia and hypoglycemia are associated with poor outcomes, which has prompted efforts targeted at optimal glycemic control.
        </p>
        <p>
         Glycemic control in critically ill patients is discussed in this topic review. Management of diabetic ketoacidosis is described separately. (See
         <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">
          "Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2564364155">
         <span class="h1">
          MECHANISM
         </span>
         <span class="headingEndMark">
          —
         </span>
         In critically ill patients, hyperglycemia is a consequence of many factors, including increased levels of cortisol, catecholamines, glucagon, and growth hormone, as well as increased gluconeogenesis, and glycogenolysis [
         <a href="#rid1">
          1
         </a>
         ]. Insulin resistance may also be a contributing factor [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Hypoglycemia in critically ill patients is mostly associated with insulin administration, sepsis, and abrupt changes in
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         , while other causes are rare. (See
         <a class="medical medical_review" href="/z/d/html/1798.html" rel="external">
          "Hypoglycemia in adults without diabetes mellitus: Determining the etiology"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          RATIONALE FOR BLOOD SUGAR CONTROL
         </span>
        </p>
        <p class="headingAnchor" id="H1781834665">
         <span class="h2">
          Avoidance of adverse effects of hyperglycemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Observational evidence from several critically ill populations has demonstrated poor clinical outcomes in association with hyperglycemia including increased mortality rate, hospital and intensive care unit (ICU) length of stay, and possibly incidence of nosocomial infection [
         <a href="#rid3">
          3-13
         </a>
         ]. The mortality risk associated with hyperglycemia appears to be independent of ICU length of stay and a known diagnosis of diabetes. However, this evidence does not prove that hyperglycemia causes poor clinical outcomes, since hyperglycemia may merely be a marker of severe illness.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medical/surgical – Hyperglycemia is common in critically ill patients (up to 80 percent). Critically ill medical and surgical patients who are hyperglycemic have a higher mortality rate than patients who are normoglycemic [
         <a href="#rid9">
          9-13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A retrospective cohort study of 1826 medical and surgical ICU patients reported higher blood glucose levels in patients who died compared with those who survived [
         <a href="#rid9">
          9
         </a>
         ]. In addition, there was a graded effect, with higher mortality among patients who had higher blood glucose levels (mean blood glucose &gt;300 mg/dL [16.6 mmol/L]) compared with those who had lower glucose levels (mean blood glucose between 80 and 99 mg/dL [4.4 and 5.5 mmol/L]; 43 versus 10 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Another observational series reported lower mortality in critically ill patients who spent more than 80 percent of their time in the desired range of 70 to 139 mg/dL, compared with those who spent less than 80 percent of their time in that range (12.4 versus 19.2 percent) [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Special populations – Hyperglycemia is also associated with worse outcomes in several subgroups of critically ill medical patients, including patients with stroke or trauma. Effects of hyperglycemia and glycemic control in these subgroups are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">
          "Initial assessment and management of acute stroke"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7956.html" rel="external">
          "Overview of inpatient management of the adult trauma patient", section on 'Glucose control'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3162725425">
         <span class="h2">
          Avoidance of the adverse effects of hypoglycemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most data that describe the impact of hypoglycemia are derived from critically ill patients treated with intensive insulin therapy (IIT), although poor outcomes can also occur in patients who develop hypoglycemia in the absence of IIT.
        </p>
        <p>
         The rate of hypoglycemia varies among studies due to varying definitions. Hypoglycemia occurs in up to 19 percent of patients when defined as a blood glucose &lt;40 mg/dL (2.2 mmol/L) [
         <a href="#rid14">
          14
         </a>
         ], or up to 32 percent of patients when defined as a blood glucose &lt;60 mg/dL (3.3 mmol/L) [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Although pooled data from two early trials (the Leuven trials) found that hypoglycemia did not cause early deaths or neurologic sequelae in critically ill patients [
         <a href="#rid14">
          14,16,17
         </a>
         ], data since then have shown that hypoglycemia is associated with an increased risk of death and can lead to seizures, brain damage, depression, and cardiac arrhythmias [
         <a href="#rid11">
          11,18-22
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a post hoc analysis of 6026 patients from one randomized trial (NICE-SUGAR), patients with moderate or severe hypoglycemia (blood glucose, 41 to 70 mg/dL [2.3 to 3.9 mmol/L] and ≤40 mg/dL [2.2 mmol/L], respectively) had a higher risk of death compared with those without hypoglycemia (adjusted hazard ratio 1.41 [95% CI 1.21-1.62] and 2.1 [95% CI 1.59-2.77], respectively) [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="local">
          'Adults'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another randomized trial (Glucontrol), mortality among patients who had an episode of hypoglycemia was 54 percent, compared with only 15 percent among patients without an episode of hypoglycemia [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="local">
          'Adults'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A nested case-control study of more than 5000 medical and surgical critically ill patients found that a blood glucose &lt;40 mg/dL (2.2 mmol/L) was an independent risk factor for death after adjustment for severity of illness, age, mechanical ventilation, renal failure, sepsis, and diabetes (adjusted odds ratio 2.28, 95% CI 1.41-3.70) [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly, in a randomized trial of tight glycemic control in critically ill children (CHiP), patients with at least one episode of hypoglycemia had increased mortality compared with those without hypoglycemia (11 versus 4 percent); this effect was most pronounced in those who had undergone cardiac surgery (11 versus 2 percent) [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="local">
          'Children'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2551871421">
         <span class="h1">
          OUR APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most clinicians in North America, Australia, and New Zealand minimize dextrose-containing products and target a blood glucose of 140 to 180 mg/dL (7.7 to 10 mmol/L) for medical and surgical adult and pediatric intensive care unit (ICU) patients [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H108712373">
         <span class="h2">
          Minimize dextrose-containing products
         </span>
         <span class="headingEndMark">
          —
         </span>
         To achieve the target blood glucose range in adult patients, we first attempt to avoid or minimize the use of intravenous fluids (IVFs) that contain glucose [
         <a href="#rid26">
          26,27
         </a>
         ]. We administer insulin only when necessary. Details regarding the administration of insulin are provided below. (See
         <a class="local">
          'Insulin therapy administration'
         </a>
         below.)
        </p>
        <p>
         The same basic principles apply to pediatric patients with the exception that growing children (particularly infants and toddlers) generally require dextrose in maintenance IVF to ensure adequate glucose delivery to avoid hypoglycemia and provide nutrition in the absence of enteral feeding; however, other sources of glucose can be limited in critically ill children (eg, IV medications). (See
         <a class="medical medical_review" href="/z/d/html/6122.html" rel="external">
          "Maintenance intravenous fluid therapy in children", section on 'Dextrose'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H867341666">
         <span class="h2">
          Target range of blood glucose
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most critically ill adult patients, we recommend a blood glucose target of 140 to 180 mg/dL (7.7 to 10 mmol/L), rather than a lower target range (eg, 80 to 110 mg/dL [4.4 to 6.1 mmol/L]) or a more liberal target range (eg, 180 to 200 mg/dL [10 to 11.1 mmol/L]). Our recommended blood glucose target is based upon data from mixed adult populations of critically ill medical and surgical patients, which have shown that targeting a lower blood glucose range of 80 to 110 mg/dL (4.4 to 6.1 mmol/L) increases the incidence of severe hypoglycemia and either increases or has no effect on mortality, when compared with the more permissive blood glucose ranges of 140 to 180 mg/dL (7.8 to 10 mmol/L) and 180 to 200 mg/dL (10 to 11.1 mmol/L).
        </p>
        <p>
         Similar data have been noted in children, although data are not as extensive as those in adults, resulting in a similar recommendation for the target range of blood glucose in that population. (See
         <a class="local">
          'Children'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3830388249">
         <span class="h3">
          Efficacy data
         </span>
         <span class="headingEndMark">
          —
         </span>
         Numerous clinical trials have compared different ranges of blood glucose in various populations of critically ill patients, some of which are described in this section. Our recommended blood glucose target of 140 to 180 mg/dL (7.7 to 10 mmol/L) is mostly based upon data from mixed adult and pediatric populations of critically ill medical and surgical patients, the details of which are discussed below.
        </p>
        <p class="headingAnchor" id="H2169445456">
         <span class="h4">
          Adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies of intensive insulin therapy (IIT) targeting select blood glucose ranges have been described in adult surgical, medical, and mixed ICU populations.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mixed adult patients
         </strong>
         – Several randomized trials and meta-analyses have evaluated IIT in mixed populations of critically ill medical and surgical patients [
         <a href="#rid18">
          18,28-37
         </a>
         ]. Most trials have reported no mortality benefit or increased mortality from stringent glycemic control regimens targeting a blood glucose level of 80 to 110 mg/dL (4.4 to 6.1 mmol/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Meta-analyses
         </strong>
         – Meta-analyses have been performed in an effort to consolidate the data from numerous randomized trials [
         <a href="#rid29">
          29,35-37
         </a>
         ]. One meta-analysis of 26 randomized trials (13,567 patients) that compared IIT with conventional glycemic control in mixed medical and surgical ICU patients reported no difference in mortality between the groups (relative risk of death 0.9, 95% CI 0.83-1.04) [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          NICE SUGAR trial
         </strong>
         – The largest randomized trial (included in the meta-analysis above) was the multicenter NICE-SUGAR trial. In this trial 6104 medical and surgical ICU patients were randomized to either IIT (target blood glucose level of 81 to 108 mg/dL [4.5 to 6 mmol/L]) or conventional glucose control (target blood glucose of &lt;180 mg/dL [&lt;10 mmol/L]) using an insulin infusion [
         <a href="#rid28">
          28
         </a>
         ]. Although the conventional glucose control group was defined only by a maximal blood glucose target, the insulin infusion was discontinued if the blood glucose level dropped below 144 mg/dL (8 mmol/L). In patients treated with IIT, 90-day mortality was higher than in patients treated with the conventional strategy (27.5 versus 24.9 percent) and also resulted in an increased number of severe hypoglycemia episodes (6.8 versus 0.5 percent). A similar outcome was reported in the subgroup of postoperative patients (see adult surgical patients bullet below).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         As an extension of this study, the long-term (24 month) neurologic and mortality outcomes of 315 patients with traumatic brain injury reported that despite a higher incidence of severe hypoglycemia with IIT, no differences were found in neurologic outcome (59 versus 53 percent in IIT versus conventional groups) or mortality (21 versus 23 percent) [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Two older trials, VISEP [
         <a href="#rid30">
          30
         </a>
         ] and Glucontrol [
         <a href="#rid18">
          18
         </a>
         ] (included in the meta-analysis above [
         <a href="#rid29">
          29
         </a>
         ]), also reported no difference in mortality and a higher incidence of severe hypoglycemia with IIT compared with conventional glucose control (target blood glucose range 140 to 200 mg/dL [7.8 to 11.1 mmol/L]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adult medical patients
         </strong>
         – Several trials of IIT in medical patients targeting a stringent blood glucose level of 80 to 110 mg/dL (4.4 to 6.1 mmol/L) have reported no mortality benefit and a significant increased frequency of hypoglycemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One single-center Belgian randomized trial of 1200 medical ICU patients (the Leuven
         <strong>
          medical
         </strong>
         trial), reported that IIT targeting a blood glucose level of 80 to 110 mg/dL (4.4 to 6.1 mmol/L) did
         <strong>
          not
         </strong>
         reduce hospital mortality compared with patients treated with conventional glucose control targeting blood glucose of 180 to 200 mg/dL (10 to 11.1 mmol/L; 37.3 versus 40 percent) [
         <a href="#rid14">
          14
         </a>
         ]. Although IIT reduced length of stay, duration of mechanical ventilation, and acute kidney failure, hypoglycemia was significantly more common in the IIT group (18.7 versus 3.1 percent). This trial was in agreement with other trials in medical patients, despite a different nutritional approach to that used elsewhere in the world. However, this outcome contrasted with that reported in similarly designed trial of IIT in surgical patients (see adult surgical patient bullet below).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The COIITSS trial randomly assigned 509 patients with septic shock who were receiving corticosteroids to either IIT using a target blood glucose level of 80 to 110 mg/dL (4.4 to 6.1 mmol/L) or conventional blood glucose control that encouraged clinicians to target a blood glucose level &lt;150 mg/dL (8.3 mmol/L) [
         <a href="#rid39">
          39
         </a>
         ]. The trial found no difference in mortality, ICU length of stay, ventilator-free days, or vasopressor-free days. IIT resulted in more episodes of severe hypoglycemia (&lt;40 mg/dL) than those in the conventional-treatment group (difference in mean number of episodes per patient, 0.15).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adult surgical patients
         </strong>
         – While trials in surgical patients have reported mixed outcome from IIT that targets lower glucose levels of 80 to 110 mg/dL (4.4 to 6.1 mmol/L), patients who received IIT had a significantly increased risk of severe hypoglycemia. Our belief is that, on balance, a similar lack of benefit noted in medical ICU patients likely also applies to the surgical population given the flaws associated with the one trial that suggested benefit [
         <a href="#rid16">
          16
         </a>
         ]. Consequently, our approach in critically ill surgical patients is similar to that in critically ill medical patients. (See
         <a class="local">
          'Our approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Favoring stringent blood glucose target
         </strong>
         – The Leuven
         <strong>
          surgical
         </strong>
         trial was a single-center Belgian trial that randomly assigned 1548 surgical ICU patients, two-thirds of whom had cardiac surgery, to receive IIT targeted at achieving 80 to 110 mg/dL (4.4 to 6.1 mmol/L) or conventional blood glucose management targeting 180 to 200 mg/dL (10 to 11.1 mmol/L) [
         <a href="#rid16">
          16
         </a>
         ]. IIT reduced both ICU mortality (4.6 versus 8 percent) and hospital mortality (7.2 versus 10.9 percent). Hypoglycemia was more frequent in the IIT group (5.1 versus 0.8 percent). However, the mortality in the conventional group was higher than that reported in other studies for most patients undergoing routine cardiac surgery (eg, ICU mortality 8 versus 1.5 percent) [
         <a href="#rid40">
          40,41
         </a>
         ], suggesting the possibility of a harmful intervention in the conventional group. For example, in this trial, all patients were treated with glucose loading by adding early total
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         (PN) to enteral nutrition, which is not typically preferred [
         <a href="#rid26">
          26,27
         </a>
         ]. Thus, the results of this trial are not generalizable to patients who receive a different nutritional approach, such as enteral nutrition started early and increased over the first few ICU days. (See
         <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">
          "Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription", section on 'Calculating calorie and protein requirements in adequately nourished patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Although a meta-analysis of five randomized trials in surgical ICU patients (1972 patients) that compared IIT with less stringent glycemic control showed similar results, trials were older and the outcomes were largely driven by the Leuven
         <strong>
          surgical
         </strong>
         trial, limiting their interpretation [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Favoring moderate blood glucose target
         </strong>
         – By contrast, when the NICE-SUGAR trial analyzed a prespecified subgroup of 2232 operative patients (ie, approximately one-third of the total group and a larger number than that in the Leuven trial), surgical patients who received IIT (target blood glucose level of 81 to 108 mg/dL [4.5 to 6 mmol/L]) had a significantly higher mortality than those who received conventional glycemic control or conventional glucose control (target blood glucose of &lt;180 mg/dL [&lt;10 mmol/L] 24.4 versus 19.8 percent, odds ratio [OR] 1.31, 95% CI 1.07-1.61) [
         <a href="#rid28">
          28
         </a>
         ]. This outcome was in keeping with medical ICU patients also included in this study, which is described in detail above (see mixed adult patients bullet above).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In one of the largest studies to date (TGC-FAST), 9230 patients (mostly surgical) were randomized to liberal glucose control (insulin initiated only when the blood-glucose level was &gt;215 mg/dL [&gt;11.9 mmol/L]) or tight glucose control (blood-glucose level targeted to 80 to 110 mg/dL [4.4 to 6.1 mmol/L]) [
         <a href="#rid42">
          42
         </a>
         ]; PN was withheld in both groups for one week. Despite a difference in the blood glucose level (140 [liberal group] versus 107 mg/dL [tight glucose control group]), the length of time that intensive care was needed and 90-day mortality were similar in the two groups, as were several other outcomes (eg, incidence of new infections, duration of respiratory and hemodynamic support). The incidence of severe hypoglycemia was low and similar in both groups (&lt;1 percent). This trial confirms a lack of benefit associated with tight glucose control and eliminates the possible confounding due to early PN seen in previous trials that showed benefit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Special populations
         </strong>
         – Data describing outcomes associated with tight glycemic control in patients with stroke have shown analogous outcomes resulting in a similar recommended target range for these patients. These data are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">
          "Initial assessment and management of acute stroke", section on 'Hyperglycemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H566313098">
         <span class="h4">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         While two small single-center studies initially reported improved mortality associated with IIT in critically ill surgical pediatric patients (up to the age of 17 years old), several larger trials (eg, SPECS [
         <a href="#rid43">
          43
         </a>
         ], CHiP [
         <a href="#rid24">
          24
         </a>
         ], and Half-PINT [
         <a href="#rid44">
          44
         </a>
         ]) have since reported a lack of benefit to tight glycemic control with IIT in this population, similar to that seen in most adult trials [
         <a href="#rid24">
          24,43,45-47
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Meta-analyses
         </strong>
         – A meta-analysis of five randomized trials comprising 3933 critically ill children reported that 30-day mortality was unaffected by tight glycemic control compared with a conventional approach (OR 0.99, 95% CI 0.74-1.32) [
         <a href="#rid48">
          48
         </a>
         ]. In addition, there was no impact on health care-associated infections (OR 0.80, 95% CI 0.64-1.00). The incidence of hypoglycemia was increased by tight glycemic control (OR 6.37, 95% CI 4.41-9.21).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CHiP
         </strong>
         – The effect of IIT was examined in one trial (CHiP) that randomized 1369 children (4 months to 16 years, 60 percent of whom had cardiac surgery) from 16 pediatric ICUs to tight or conventional glucose control [
         <a href="#rid24">
          24
         </a>
         ]. At 30 days, tight glucose control (ie, blood glucose 72 to 126 mg/dL [4 to 7 mmol/L]) did not affect the composite outcome (mortality and number of ventilator-free days; mean difference 0.36 days alive and free of mechanical ventilation) compared with conventional glycemic control (180 to 216 mg/dL [10 to 12 mmol/L]), a result that was consistent across subgroups. Severe hypoglycemia (blood glucose &lt;36 mg/dL [2 mmol/L]) occurred more frequently in the tight-glycemic-control group (7 versus 2 percent). However, the analysis is limited by achieved glucose levels that were similar between the groups (107 and 114 mg/dL [5.9 and 6.3 mmol/L]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HALF-PINT
         </strong>
         – The HALF-PINT trial compared high and low blood glucose target levels in 713 hyperglycemic critically ill children (2 weeks to 17 years with two blood glucose measurements &gt;150 mg/dL [8.3 mmol/L] before intervention). Patients who had undergone cardiac surgery were excluded. There was no difference in mortality, ICU-free days, severity of organ dysfunction, and number of ventilator-free days among those treated with a lower target blood glucose level of 80 to 110 mg/dL (4.4 to 6.1 mmol/L) compared with a higher target level of 150 to 180 mg/dL (8.3 to 10 mmol/L) [
         <a href="#rid44">
          44
         </a>
         ]. Also reported in the lower target group were higher rates of hypoglycemia (5 versus 2 percent) and health care-associated infections (3 versus 1 percent). Similar to CHiP, limiting the analysis was a lower-than-expected mean blood glucose level (123 mg/dL [6.8 mmol/L]) in the conventional treatment arm (which may reflect a reduction in the use of PN in pediatric ICU care) and early cessation of the trial on the basis of low likelihood of benefit and possibility of harm.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2400308030">
         <span class="h2">
          Insulin therapy administration
         </span>
        </p>
        <p class="headingAnchor" id="H1799184133">
         <span class="h3">
          Initiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no universally accepted insulin regimen for glycemic control in critically ill patients. However, in general, we use short-acting preparations as either an intermittent subcutaneous regimen (eg, four- to six-hour dosing) or continuous infusion to achieve the optimal target value (ie, 140 to 180 mg/dL [7.7 to 10 mmol/L]) [
         <a href="#rid49">
          49
         </a>
         ]. Our concern regarding avoidance of using longer-acting insulin preparations during early phases of critical illness before patients have stabilized is that the insulin requirement may change acutely (eg, discontinuation of enteral or parenteral feeding or glucocorticoids), thereby placing the patient at risk of developing hypoglycemia. (See
         <a class="local">
          'Target range of blood glucose'
         </a>
         above.)
        </p>
        <p>
         Choosing between an intermittent regimen and an infusion depends upon factors including the level of blood glucose, the presence of diabetes, agents that induce hyperglycemia, and response to the insulin regimen used. The approach is typically individualized since patients may require different strategies.
        </p>
        <p>
         In general, our approach in
         <strong>
          adults
         </strong>
         is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients whose blood glucose is consistently above 180 mg/dL (&gt;10 mmol/L) for 12 hours or more, we generally initiate an intermittent sliding-scale subcutaneous regimen, provided the patient does not have diabetic ketoacidosis. (See
         <a class="medical medical_review" href="/z/d/html/1770.html" rel="external">
          "Management of diabetes mellitus in hospitalized patients", section on 'Sliding-scale insulin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If blood glucose continues be uncontrolled during the ensuing 24 hours, we typically escalate to a more aggressive intermittent sliding-scale regimen (ie, increase the dose and/or frequency of insulin) before initiating an insulin infusion. (See
         <a class="medical medical_review" href="/z/d/html/1770.html" rel="external">
          "Management of diabetes mellitus in hospitalized patients", section on 'Insulin infusion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For some patients, the threshold to start an insulin infusion may be lower. This includes patients with diabetes, patients with labile values, and patients with severely elevated blood glucose levels (eg, &gt;250 mg/dL [&gt;13.9 mmol/L]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who need an insulin infusion, we encourage institutions to develop their own protocol or algorithm (eg, with a sliding-scale structure) designed to optimally treat their specific patient cohorts using protocols from published series. Importantly, insulin infusion protocols differ from those for patients with diabetic ketoacidosis. (See
         <a class="local">
          'Efficacy data'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients receiving PN, we typically add short-acting insulin to the PN regimen so that insulin is administered as an infusion, although subcutaneous protocols are also an option.
        </p>
        <p>
        </p>
        <p>
         For
         <strong>
          children and infants
         </strong>
         , the principles of insulin treatment are similar, with insulin generally administered as a continuous infusion dosed in a general range of 0.01 to 0.1 units/kg/hour, although rarely doses as high as 0.3 units/kg/hour may be needed. Particular attention should be paid to carbohydrate content in enteral feeds and dextrose content in continuous infusions, as abrupt initiation or discontinuation of these feeds or infusions can have significant impact on blood glucose levels. (See
         <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">
          "Neonatal hyperglycemia"
         </a>
         .)
        </p>
        <p>
         Management of insulin infusions in hospitalized patients is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1770.html" rel="external">
          "Management of diabetes mellitus in hospitalized patients", section on 'Insulin infusion'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Insulin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H851302717">
         <span class="h3">
          Transitioning to longer-acting regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the acute illness has resolved and insulin requirements are stabilized, we generally transition to longer-acting insulin (if required), which has been shown to be safe, particularly in patients who are being enterally fed [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         In patients who are parenterally fed, the same strategy can be used. Alternatively, short-acting insulin can be added to parenteral feeding, which has the advantage of avoiding insulin administration when parenteral feeding is stopped (eg, loss of central access); in the latter case, we partially rather than completely meet the patient's insulin needs and supplement with subcutaneous insulin to meet target blood glucose values.
        </p>
        <p>
         Transitioning to longer-acting formulations in hospitalized patients with diabetes is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Converting to subcutaneous insulin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H169453328">
         <span class="h2">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Careful monitoring of blood glucose is mandatory to achieve the target range and avoid hypoglycemia.
        </p>
        <p>
         While several devices are available for monitoring glucose, none has proven efficacy over the other [
         <a href="#rid51">
          51-53
         </a>
         ]. Arterial blood glucose is considered more accurate than other types of sampling but is not always pragmatic. We typically use standard bedside hospital-certified, and ideally ICU-certified, blood glucose meters and check arterial or a venous sample if erroneous readings are suspected (eg, very low or high readings beyond the parameters of the glucometer or IV
         <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">
          vitamin C
         </a>
         [ascorbate] is being administered which can falsely elevate blood glucose readings [
         <a href="#rid54">
          54
         </a>
         ]).
        </p>
        <p>
         In general, blood glucose is monitored every hour while on insulin infusions using local pharmacy-directed protocols, while measurements every four to six hours are typically used in patients receiving intermittent insulin regimens. Further de-escalation can occur once the patients is stable on a long-acting regimen. (See
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H721565951">
         <span class="h2">
          Treating hypoglycemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal management strategy for insulin-induced hypoglycemia is unknown. In adults and children, we treat hypoglycemia promptly and in a similar fashion to hypoglycemia from other causes. (See
         <a class="medical medical_review" href="/z/d/html/1805.html" rel="external">
          "Hypoglycemia in adults with diabetes mellitus", section on 'With IV access'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5805.html" rel="external">
          "Approach to hypoglycemia in infants and children", section on 'Glucose therapy'
         </a>
         .)
        </p>
        <p>
         We do not typically use specific protocols (eg, a sliding scale of specific dextrose loads for select levels of hypoglycemia) to treat hypoglycemia since their impact is unproven. However, one retrospective analysis of 105 patients reported that the implementation of a hypoglycemia protocol led to reduced glucose variability compared with a conventional approach [
         <a href="#rid55">
          55
         </a>
         ]. Larger randomized trials demonstrating a mortality benefit are required before such protocols can be routinely used for the management of hypoglycemia in the ICU.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rationale for glycemic control
         </strong>
         – In critically ill children and adults, hyperglycemia and hypoglycemia are associated with poor clinical outcomes, including increased risk of death. (See
         <a class="local">
          'Rationale for blood sugar control'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Our approach
         </strong>
         – Our suggested approach is as follows (see
         <a class="local">
          'Our approach'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Minimize glucose loads
         </strong>
         – In adults, we first attempt to avoid or minimize the use of intravenous fluid (IVF) that contains glucose and only initiate insulin if uncontrolled hyperglycemia persists. The same basic principles apply in pediatric patients with the exception that growing children (particularly infants and toddlers) generally require dextrose in IVF to avoid hypoglycemia and provide nutrition (in the absence of enteral feeding), but other sources of glucose can be limited (eg, IV medications). (See
         <a class="local">
          'Minimize dextrose-containing products'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Optimal blood glucose target
         </strong>
         – For most hyperglycemic critically ill patients (children and adults), we recommend a moderately permissive strategy (ie, target blood glucose 140 to 180 mg/dL [7.7 to 10 mmol/L]) rather than intensive insulin therapy (IIT) targeting blood glucose 80 to 110 mg/dL (4.4 to 6.1 mmol/L) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). We also suggest a moderately permissive target rather than a more liberal target (ie, 180 to 200 mg/dL [10 to 11.1 mmol/L]) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Our preference for this approach is based upon clinical trials in critically ill children and adults demonstrating that IIT targeting stringent blood glucose levels is not beneficial and is associated with an increased risk of harm due to severe hypoglycemia. (See
         <a class="local">
          'Efficacy data'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Administration and monitoring
         </strong>
         – A widely accepted insulin regimen has not been established, but we prefer to use short-acting insulin preparations.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The approach in adults is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We typically initiate an intermittent subcutaneous sliding-scale insulin regimen in patients whose blood glucose is consistently above 180 mg/dL (&gt;10 mmol/L) for 12 to 24 hours and escalate to an aggressive regimen, and eventually infusion, if blood glucose continues be uncontrolled. Once the acute illness has resolved and insulin requirement stabilized, we typically transition to a longer-acting insulin, if needed. (See
         <a class="local">
          'Insulin therapy administration'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Converting to subcutaneous insulin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Careful monitoring of blood glucose is necessary to achieve glycemic control while avoiding the potential harmful effects of hypoglycemia. While several devices are available for monitoring glucose, we typically use bedside glucose meters since no tool has proven efficacy over another. (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         While the optimal management strategy for insulin-induced hypoglycemia is unknown, we treat hypoglycemia in critically ill adult patients in a similar fashion to hypoglycemia from other causes (eg, 25 to 50 g
         <a class="drug drug_general" data-topicid="8711" href="/z/d/drug information/8711.html" rel="external">
          IV dextrose
         </a>
         ). We do not use specific protocols designed to manage hypoglycemia since their efficacy is unproven. (See
         <a class="medical medical_review" href="/z/d/html/1805.html" rel="external">
          "Hypoglycemia in adults with diabetes mellitus", section on 'With IV access'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For
         <strong>
          children and infants
         </strong>
         , the principles of insulin treatment are similar, with insulin generally administered as a continuous infusion dosed in a general range of 0.01 to 0.1 units/kg/hour, although rarely doses as high as 0.3 units/kg/hour may be needed. Particular attention should be paid to carbohydrate content in enteral feeds and dextrose content in continuous infusions, as abrupt initiation or discontinuation of these feeds or infusions can have significant impact on blood glucose levels. We also treat hypoglycemia in a similar fashion to hypoglycemia from other causes. (See
         <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">
          "Neonatal hyperglycemia", section on 'Insulin therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5805.html" rel="external">
          "Approach to hypoglycemia in infants and children", section on 'Glucose therapy'
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001; 17:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saberi F, Heyland D, Lam M, et al. Prevalence, incidence, and clinical resolution of insulin resistance in critically ill patients: an observational study. JPEN J Parenter Enteral Nutr 2008; 32:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yendamuri S, Fulda GJ, Tinkoff GH. Admission hyperglycemia as a prognostic indicator in trauma. J Trauma 2003; 55:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laird AM, Miller PR, Kilgo PD, et al. Relationship of early hyperglycemia to mortality in trauma patients. J Trauma 2004; 56:1058.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sung J, Bochicchio GV, Joshi M, et al. Admission hyperglycemia is predictive of outcome in critically ill trauma patients. J Trauma 2005; 59:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bochicchio GV, Sung J, Joshi M, et al. Persistent hyperglycemia is predictive of outcome in critically ill trauma patients. J Trauma 2005; 58:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rovlias A, Kotsou S. The influence of hyperglycemia on neurological outcome in patients with severe head injury. Neurosurgery 2000; 46:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeremitsky E, Omert LA, Dunham CM, et al. The impact of hyperglycemia on patients with severe brain injury. J Trauma 2005; 58:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003; 78:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falciglia M, Freyberg RW, Almenoff PL, et al. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Crit Care Med 2009; 37:3001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Y, Bai Z, Li M, et al. U-shaped relationship between early blood glucose and mortality in critically ill children. BMC Pediatr 2015; 15:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker CD, Sabang RL, Nogueira Cordeiro MF, et al. Hyperglycemia in Medically Critically Ill Patients: Risk Factors and Clinical Outcomes. Am J Med 2020; 133:e568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanspa MJ, Krinsley JS, Hersh AM, et al. Percentage of Time in Range 70 to 139 mg/dL Is Associated With Reduced Mortality Among Critically Ill Patients Receiving IV Insulin Infusion. Chest 2019; 156:878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grey NJ, Perdrizet GA. Reduction of nosocomial infections in the surgical intensive-care unit by strict glycemic control. Endocr Pract 2004; 10 Suppl 2:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van den Berghe G, Wilmer A, Milants I, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes 2006; 55:3151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preiser JC, Devos P, Ruiz-Santana S, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 2009; 35:1738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanhorebeek I, Langouche L, Van den Berghe G. Tight blood glucose control with insulin in the ICU: facts and controversies. Chest 2007; 132:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med 2007; 35:2262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dowdy DW, Dinglas V, Mendez-Tellez PA, et al. Intensive care unit hypoglycemia predicts depression during early recovery from acute lung injury. Crit Care Med 2008; 36:2726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermanides J, Bosman RJ, Vriesendorp TM, et al. Hypoglycemia is associated with intensive care unit mortality. Crit Care Med 2010; 38:1430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           The NICE-SUGAR Study Investigators. Hypoglycemia and risk of death in critically ill patients. N Engl J Med 2012; 367:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macrae D, Grieve R, Allen E, et al. A randomized trial of hyperglycemic control in pediatric intensive care. N Engl J Med 2014; 370:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qaseem A, Humphrey LL, Chou R, et al. Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011; 154:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heyland DK, Dhaliwal R, Drover JW, et al. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr 2003; 27:355.
          </a>
         </li>
         <li class="breakAll">
          Published version of the clinical practice guidelines. In: Nutrition CPGs. www.criticalcarenutrition.com (Accessed on October 14, 2008).
         </li>
         <li>
          <a class="nounderline abstract_t">
           NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 2009; 180:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arabi YM, Dabbagh OC, Tamim HM, et al. Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. Crit Care Med 2008; 36:3190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu WK, Li WQ, Wang XD, et al. [Influence and mechanism of a tight control of blood glucose by intensive insulin therapy on human sepsis]. Zhonghua Wai Ke Za Zhi 2005; 43:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savioli M, Cugno M, Polli F, et al. Tight glycemic control may favor fibrinolysis in patients with sepsis. Crit Care Med 2009; 37:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalfon P, Giraudeau B, Ichai C, et al. Tight computerized versus conventional glucose control in the ICU: a randomized controlled trial. Intensive Care Med 2014; 40:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008; 300:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marik PE, Preiser JC. Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis. Chest 2010; 137:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kansagara D, Fu R, Freeman M, et al. Intensive insulin therapy in hospitalized patients: a systematic review. Ann Intern Med 2011; 154:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           NICE-SUGAR Study Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group and the Canadian Critical Care Trials Group, Finfer S, Chittock D, et al. Intensive versus conventional glucose control in critically ill patients with traumatic brain injury: long-term follow-up of a subgroup of patients from the NICE-SUGAR study. Intensive Care Med 2015; 41:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           COIITSS Study Investigators, Annane D, Cariou A, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010; 303:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Likosky DS, Nugent WC, Clough RA, et al. Comparison of three measurements of cardiac surgery mortality for the Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg 2006; 81:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker ER, McPherson MA, Rahimi A. Influence of source and type of admission on in-hospital mortality for coronary artery bypass surgery patients: national results from 1.7 million CABG patients, 1998 to 2002. J Card Surg 2007; 22:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunst J, Debaveye Y, Güiza F, et al. Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU. N Engl J Med 2023; 389:1180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agus MS, Steil GM, Wypij D, et al. Tight glycemic control versus standard care after pediatric cardiac surgery. N Engl J Med 2012; 367:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agus MS, Wypij D, Hirshberg EL, et al. Tight Glycemic Control in Critically Ill Children. N Engl J Med 2017; 376:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vlasselaers D, Milants I, Desmet L, et al. Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study. Lancet 2009; 373:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeschke MG, Kulp GA, Kraft R, et al. Intensive insulin therapy in severely burned pediatric patients: a prospective randomized trial. Am J Respir Crit Care Med 2010; 182:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srinivasan V, Agus MS. Tight glucose control in critically ill children--a systematic review and meta-analysis. Pediatr Diabetes 2014; 15:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao Y, Wu Y, Xiang B. Tight glycemic control in critically ill pediatric patients: a meta-analysis and systematic review of randomized controlled trials. Pediatr Res 2018; 83:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med 2012; 40:3251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickerson RN, Wilson VC, Maish GO 3rd, et al. Transitional NPH insulin therapy for critically ill patients receiving continuous enteral nutrition and intravenous regular human insulin. JPEN J Parenter Enteral Nutr 2013; 37:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bochicchio GV, Nasraway S, Moore L, et al. Results of a multicenter prospective pivotal trial of the first inline continuous glucose monitor in critically ill patients. J Trauma Acute Care Surg 2017; 82:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garingarao CJ, Buenaluz-Sedurante M, Jimeno CA. Accuracy of point-of-care blood glucose measurements in critically ill patients in shock. J Diabetes Sci Technol 2014; 8:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okabayashi T, Shima Y. Are closed-loop systems for intensive insulin therapy ready for prime time in the ICU? Curr Opin Clin Nutr Metab Care 2014; 17:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hager DN, Martin GS, Sevransky JE, Hooper MH. Glucometry When Using Vitamin C in Sepsis: A Note of Caution. Chest 2018; 154:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold P, Paxton RA, McNorton K, et al. The effect of a hypoglycemia treatment protocol on glycemic variability in critically ill patients. J Intensive Care Med 2015; 30:156.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1600 Version 48.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11219223" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Stress-induced hyperglycemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18443133" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prevalence, incidence, and clinical resolution of insulin resistance in critically ill patients: an observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12855878" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Admission hyperglycemia as a prognostic indicator in trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15179246" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Relationship of early hyperglycemia to mortality in trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16096543" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Admission hyperglycemia is predictive of outcome in critically ill trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920404" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Persistent hyperglycemia is predictive of outcome in critically ill trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10690722" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The influence of hyperglycemia on neurological outcome in patients with severe head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15674149" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The impact of hyperglycemia on patients with severe brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14661676" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19661802" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26204931" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : U-shaped relationship between early blood glucose and mortality in critically ill children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32278843" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hyperglycemia in Medically Critically Ill Patients: Risk Factors and Clinical Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31201784" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Percentage of Time in Range 70 to 139 mg/dL Is Associated With Reduced Mortality Among Critically Ill Patients Receiving IV Insulin Infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16452557" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Intensive insulin therapy in the medical ICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15251640" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Reduction of nosocomial infections in the surgical intensive-care unit by strict glycemic control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11794168" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Intensive insulin therapy in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17065355" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19636533" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17625087" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Tight blood glucose control with insulin in the ICU: facts and controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17717490" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Severe hypoglycemia in critically ill patients: risk factors and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18766087" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Intensive care unit hypoglycemia predicts depression during early recovery from acute lung injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20386307" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Hypoglycemia is associated with intensive care unit mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Hypoglycemia and risk of death in critically ill patients
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24401049" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A randomized trial of hyperglycemic control in pediatric intensive care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21320941" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12971736" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12971736" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19318384" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Intensive versus conventional glucose control in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19318387" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18184958" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Intensive insulin therapy and pentastarch resuscitation in severe sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18936702" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15774170" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : [Influence and mechanism of a tight control of blood glucose by intensive insulin therapy on human sepsis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19114908" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Tight glycemic control may favor fibrinolysis in patients with sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24420499" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Tight computerized versus conventional glucose control in the ICU: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18728267" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Benefits and risks of tight glucose control in critically ill adults: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20018803" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21320942" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Intensive insulin therapy in hospitalized patients: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26088909" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Intensive versus conventional glucose control in critically ill patients with traumatic brain injury: long-term follow-up of a subgroup of patients from the NICE-SUGAR study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20103758" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16564278" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Comparison of three measurements of cardiac surgery mortality for the Northern New England Cardiovascular Disease Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17488415" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Influence of source and type of admission on in-hospital mortality for coronary artery bypass surgery patients: national results from 1.7 million CABG patients, 1998 to 2002.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37754283" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22957521" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Tight glycemic control versus standard care after pediatric cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28118549" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Tight Glycemic Control in Critically Ill Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19176240" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20395554" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Intensive insulin therapy in severely burned pediatric patients: a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24783254" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Tight glucose control in critically ill children--a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29244792" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Tight glycemic control in critically ill pediatric patients: a meta-analysis and systematic review of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23164767" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22914894" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Transitional NPH insulin therapy for critically ill patients receiving continuous enteral nutrition and intravenous regular human insulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28328679" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Results of a multicenter prospective pivotal trial of the first inline continuous glucose monitor in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25172876" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Accuracy of point-of-care blood glucose measurements in critically ill patients in shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24378668" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Are closed-loop systems for intensive insulin therapy ready for prime time in the ICU?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30044741" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Glucometry When Using Vitamin C in Sepsis: A Note of Caution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24277155" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The effect of a hypoglycemia treatment protocol on glycemic variability in critically ill patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
